Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-naive Patients With Breast Cancer

Mise à jour : Il y a 5 ans
Référence : NCT00359190

Femme et Homme

Extrait

This study will examine the inhibition of ErbB1 and ErbB2 phosphorylation and downstream mediators of tumor cell growth and survival tumor tissue in treatment-naive breast cancer patients for three dosing schedules of lapatinib.


Critère d'inclusion

  • Neoplasms, Breast

Liens